Cellectis (CLLS) Receivables - Other (2014 - 2026)
Cellectis (CLLS) posted quarterly Receivables - Other of $7.6 million for Q1 2026, down 49.77% year-over-year from $15.1 million in Q1 2025, and down 2.64% quarter-over-quarter from $7.8 million in Q4 2025.
Cellectis (CLLS) Receivables - Other (2014 - 2026) Analysis & Trends
Cellectis' Receivables - Other history runs 13 years deep, the most recent figure standing at $7.6 million for Q1 2026.
- In Q1 2026, Receivables - Other fell 49.77% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (down 49.77% YoY), while the FY2025 annual figure was $7.8 million, down 46.28% from the prior year.
- Receivables - Other for Q1 2026 stood at $7.6 million, down from $7.8 million in the prior quarter.
- The five-year high for Receivables - Other was $23.1 million in Q1 2024, with the low at $7.6 million in Q1 2026.
- The 5-year median for Receivables - Other is $15.1 million (2025), against an average of $15.2 million.
- The sharpest annual moves came in 2022 and 2026: Receivables - Other jumped 98.87% in 2022, then tumbled 49.77% in 2026.
- Cellectis' Receivables - Other stood at $14.5 million in 2022, then jumped by 44.18% to $20.9 million in 2023, then tumbled by 30.52% to $14.5 million in 2024, then slumped by 46.28% to $7.8 million in 2025, then slipped by 2.64% to $7.6 million in 2026.
- Business Quant data shows CLLS's Receivables - Other at $7.6 million in Q1 2026, $7.8 million in Q4 2025, and $16.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.59 Mn |
| Mar 31, 2026 | 7.59 Mn |
| Dec 31, 2025 | 7.80 Mn |
| Dec 31, 2025 | 7.80 Mn |
| Sep 30, 2025 | 16.41 Mn |
| Sep 30, 2025 | 16.41 Mn |
| Jun 30, 2025 | 16.38 Mn |
| Jun 30, 2025 | 16.38 Mn |
| Mar 31, 2025 | 15.12 Mn |
| Mar 31, 2025 | 15.12 Mn |
| Dec 31, 2024 | 14.52 Mn |
| Dec 31, 2024 | 14.52 Mn |
| Sep 30, 2024 | 15.66 Mn |
| Sep 30, 2024 | 15.66 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Mar 31, 2024 | 23.10 Mn |
| Mar 31, 2024 | 23.10 Mn |
| Dec 31, 2023 | 20.90 Mn |
| Dec 31, 2023 | 20.90 Mn |